mirtazapine
Adjunctive therapy • Brands: Remeron
Last reviewed: 2025-10-05
General information
- Class: Adjunctive therapy
- Common US brands: Remeron
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-10-05
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Central presynaptic alpha-2 antagonist; enhances noradrenergic and serotonergic transmission (NaSSA).
Metabolism & Half‑life
- Metabolism: CYP1A2, CYP2D6, CYP3A4
- Half‑life: Single-dose mean 30 h; Single-dose range 20–40 h; Steady-state mean 37 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Remeron (mirtazapine) prescribing information — DailyMed (2025)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)
- CANMAT 2024 Clinical Guidelines for the Management of Major Depressive Disorder — Canadian Journal of Psychiatry (2024)
- Comparative efficacy and acceptability of antidepressants for major depressive disorder: a systematic review and network meta-analysis — The Lancet (2018)